Wegovy trial result gives boost to Novo Nordisk amid U.S. market woes

1. Wegovy shows 57% greater heart risk reduction over tirzepatide. 2. Real-world study data supports Wegovy's efficacy, boosting investor confidence. 3. Novo Nordisk faces challenges in U.S. market with growing competition. 4. Shares rose 3% but still vulnerable due to recent U.S. struggles. 5. Sector uncertainty includes tariffs and potential regulatory changes affecting profitability.